FMC Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.1%projected annual EPS growth
Analyst Coverage
14analysts covering
FY Revenue (est.)
$3.6Bnext fiscal year
FY EPS (est.)
$1.29next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Full-Year Revenue Guidance Quarterly3.7BTarget: 3.60 billion to 3.80 billion
Full-Year Adjusted EBITDA Guidance Quarterly700MTarget: 670 million to 730 million
Debt Reduction Target AnnuallyTarget: 1.00 billion
Watch Items
- Rynaxypyr Patent Expiration and Generic CompetitionTrigger: Accelerated market share loss or pricing pressure in Brazil and North America in H2 2026Action: Monitor branded Rynaxypyr pricing adjustments and volume trends relative to generic entrants.
- Non-Core Asset Divestitures and India Commercial Business SaleTrigger: Completion of the $252 million India commercial business sale to Crystal Crop ProtectionAction: Track progress of the remaining $700 million in advanced negotiations to meet the $1 billion debt paydown target.
- New Active Ingredient CommercializationTrigger: New active ingredient sales falling below the $300 million to $400 million guidance range for 2026Action: Evaluate commercial rollout traction of Isoflex, fluindapyr, Dodhylex, and rimisoxafen.
Research as of 20 Jun 2026